

INSULET CORP  
Form 10-Q  
August 12, 2015  
Table of Contents

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

Form 10-Q

---

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934

For the quarterly period ended June 30, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934

Commission File Number 001-33462

---

INSULET CORPORATION  
(Exact name of Registrant as specified in its charter)

---

Delaware (State or Other Jurisdiction of Incorporation or Organization)	04-3523891 (I.R.S. Employer Identification No.)
---	---

---

600 Technology Park Drive, Suite 200 Billerica, Massachusetts (Address of Principal Executive Offices)	01821 (Zip Code)
--	---------------------

Registrant's Telephone Number, Including Area Code: (978) 600-7000

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of August 10, 2015, the registrant had 56,895,050 shares of common stock outstanding.

---

Table of Contents

INSULET CORPORATION  
QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED  
June 30, 2015  
TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

<u>Item 1. Consolidated Financial Statements (Unaudited)</u>	<u>3</u>
<u>Consolidated Balance Sheets as of June 30, 2015 and December 31, 2014</u>	<u>3</u>
<u>Consolidated Statements of Operations for the three and six months ended June 30, 2015 and 2014</u>	<u>4</u>
<u>Consolidated Statements of Cash Flows for the six months ended June 30, 2015 and 2014</u>	<u>5</u>
<u>Condensed Notes to Consolidated Financial Statements (Unaudited)</u>	<u>6</u>
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>22</u>
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	<u>33</u>
<u>Item 4. Controls and Procedures</u>	<u>33</u>

PART II. OTHER INFORMATION

<u>Item 1. Legal Proceedings</u>	<u>34</u>
<u>Item 1A. Risk Factors</u>	<u>34</u>
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>34</u>
<u>Item 3. Defaults Upon Senior Securities</u>	<u>34</u>
<u>Item 4. Mine Safety Disclosures</u>	<u>34</u>
<u>Item 5. Other Information</u>	<u>34</u>
<u>Item 6. Exhibits</u>	<u>35</u>
<u>Signatures</u>	<u>36</u>

---

Table of Contents

## PART I - FINANCIAL INFORMATION

## Item 1. Consolidated Financial Statements (Unaudited)

## INSULET CORPORATION

## CONSOLIDATED BALANCE SHEETS

	June 30, 2015	December 31, 2014
(In thousands, except share and per share data)		
	(Unaudited)	
<b>ASSETS</b>		
Current Assets		
Cash and cash equivalents	\$145,137	\$151,193
Accounts receivable, net	31,826	39,882
Inventories, net	23,435	13,099
Prepaid expenses and other current assets	3,431	4,022
Total current assets	203,829	208,196
Property and equipment, net	42,040	37,069
Intangible assets, net	12,301	14,064
Goodwill	37,536	37,536
Other assets	4,687	5,291
Total assets	\$300,393	\$302,156
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current Liabilities		
Accounts payable	\$17,916	\$14,659
Accrued expenses and other current liabilities	26,443	24,703
Deferred revenue	2,088	1,554
Current portion of capital lease obligations	6,235	3,380
Total current liabilities	52,682	44,296
Capital lease obligations	2,315	2,263
Long-term debt, net of discount	172,220	168,994
Other long-term liabilities	2,921	2,774
Total liabilities	230,138	218,327
Commitments and contingencies (Note 11)		
Stockholders' Equity		
Preferred stock, \$.001 par value:		
Authorized: 5,000,000 shares at June 30, 2015 and December 31, 2014.	—	—
Issued and outstanding: zero shares at June 30, 2015 and December 31, 2014.		
Common stock, \$.001 par value:		
Authorized: 100,000,000 shares at June 30, 2015 and December 31, 2014.		
Issued and outstanding: 56,876,012 and 56,299,022 shares at June 30, 2015 and December 31, 2014, respectively.	57	56
Additional paid-in capital	675,489	661,798
Accumulated deficit	(605,291	) (578,025 )
Total stockholders' equity	70,255	83,829
Total liabilities and stockholders' equity	\$300,393	\$302,156

The accompanying condensed notes are an integral part of these consolidated financial statements.

Table of ContentsINSULET CORPORATION  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(UNAUDITED)

(In thousands, except share and per share data)	Three Months Ended June 30,		Six Months Ended June 30,	
	2015	2014	2015	2014
Revenue	\$75,588	\$72,013	\$136,803	\$141,174
Cost of revenue	41,213	36,248	69,621	72,601
Gross profit	34,375	35,765	67,182	68,573
Operating expenses:				
Research and development	12,069	6,677	20,276	13,456
General and administrative	12,856	19,512	28,685	33,771
Sales and marketing	21,811	14,856	39,212	28,512
Total operating expenses	46,736	41,045	88,173	75,739
Operating loss	(12,361)	) (5,280)	) (20,991)	) (7,166)
Interest income	41	29	77	60
Interest expense	(3,075)	) (3,975)	) (6,268)	) (8,464)
Other income (expense), net	—	(890)	) 5	(625)
Loss on extinguishment of long-term debt	—	(18,943)	) —	(18,943)
Interest and other expense, net	(3,034)	) (23,779)	) (6,186)	) (27,972)
Loss before income taxes	(15,395)	) (29,059)	) (27,177)	) (35,138)
Income tax expense	(37)	) (52)	) (89)	) (117)
Net loss	\$(15,432)	) \$(29,111)	) \$(27,266)	) \$(35,255)
Net loss per share basic and diluted	\$(0.27)	) \$(0.53)	) \$(0.48)	) \$(0.64)
Weighted-average number of shares used in calculating net loss per share	56,808,489	55,425,949	56,653,430	55,258,419

The accompanying condensed notes are an integral part of these consolidated financial statements.

Table of Contents

INSULET CORPORATION  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
(UNAUDITED)

(In thousands)	Six Months Ended June 30,	
	2015	2014
Cash flows from operating activities		
Net loss	\$(27,266	) \$(35,255
Adjustments to reconcile net loss to net cash used in operating activities		
Depreciation and amortization	7,114	6,100
Non-cash interest and other expense	3,789	5,869
Stock-based compensation expense	9,630	8,577
Loss on extinguishment of debt	—	18,943
Provision for bad debts	1,180	1,804
Changes in operating assets and liabilities:		
Accounts receivable	6,876	(10,534
Inventories	(10,336	) 699
Deferred revenue	534	355
Prepaid expenses and other assets	632	(1,006
Accounts payable, accrued expenses and other current liabilities	4,997	4,361
Other long-term liabilities	147	(422
Net cash used in operating activities	(2,703	) (509
Cash flows from investing activities		
Purchases of property and equipment	(4,601	) (5,745
Net cash used in investing activities	(4,601	) (5,745
Cash flows from financing activities		
Principal payments of capital lease obligations	(2,814	) (1,262
Proceeds from issuance of long-term debt, net of issuance costs	—	194,570
Repayment of long-term debt	—	(160,685
Proceeds from issuance of common stock, net of offering costs	6,489	5,339
Payment of withholding taxes in connection with vesting of restricted stock units	(2,427	) (5,890
Net cash provided by financing activities	1,248	32,072
Net (decrease) increase in cash and cash equivalents	(6,056	) 25,818
Cash and cash equivalents, beginning of period	151,193	149,727
Cash and cash equivalents, end of period	\$145,137	\$175,545
Non-cash investing and financing activities		
Allocation to equity for conversion feature for the 2% Notes	\$—	\$35,638
Purchases of property and equipment under capital lease	\$5,721	\$—

The accompanying condensed notes are an integral part of these consolidated financial statements.

Table of Contents

INSULET CORPORATION

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Nature of the Business

Insulet Corporation, the "Company," is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the "OmniPod System"), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager ("PDM"). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to 42 inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter.

The Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, "Neighborhood Diabetes") in June 2011, in order to expand the Company's full-suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.

Commercial sales of the OmniPod System began in the United States in 2005. The Company sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The OmniPod System is currently available in multiple countries in Europe and in Canada.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015, or for any other subsequent interim period.

The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with the Company's consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.

Use of Estimates in Preparation of Financial Statements

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.

Principles of Consolidation

The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents

For the purpose of the financial statement classification, the Company considers all highly liquid investment instruments with original maturities of 90 days or less, when purchased, to be cash equivalents. Cash equivalents



## Table of Contents

include money market accounts, which are carried at cost which approximates their fair value. Outstanding letters of credit, related to security deposits for lease obligations, totaled \$1.2 million as of June 30, 2015 and December 31, 2014.

### Property and Equipment

Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the respective assets. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Assets acquired under capital leases are amortized in accordance with the respective class of owned assets and the amortization is included with depreciation expense. Maintenance and repair costs are expensed as incurred.

### Goodwill

Goodwill represents the excess of the cost of the acquired Neighborhood Diabetes businesses over the fair value of identifiable net assets acquired. The Company follows the provisions of FASB ASC 350-20, Intangibles - Goodwill and Other ("ASC 350-20"). The Company performs an assessment of its goodwill for impairment on at least an annual basis or whenever events or changes in circumstances indicate there might be impairment.

The Company continues to operate in one segment, which is considered to be the sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level. The Company performs an annual goodwill impairment test unless interim indicators of impairment exist. The Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of its sole reporting unit is less than its carrying amount. This qualitative analysis is used as a basis for determining whether it is necessary to perform the two-step goodwill impairment analysis. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the two-step goodwill impairment test will be performed. The first step compares the carrying value of the reporting unit to its fair value using a discounted cash flow analysis. If the reporting unit's carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. There were no indicators of goodwill impairment during the three and six months ended June 30, 2015 or 2014.

### Revenue Recognition

The Company generates nearly all of its revenue from sales of its OmniPod System and other diabetes related products including blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals to customers and third-party distributors who resell the products to patients with diabetes.

Revenue recognition requires that persuasive evidence of a sales arrangement exists, delivery of goods occurs through transfer of title and risk and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. With respect to these criteria:

The evidence of an arrangement generally consists of a physician order form, a patient information form and, if applicable, third-party insurance approval for sales directly to patients or a purchase order for sales to a third-party distributor.

• Transfer of title and risk and rewards of ownership are passed to the patient or third-party distributor upon shipment of the products.

The selling prices for all sales are fixed and agreed with the patient or third-party distributor and, if applicable, the patient's third-party insurance provider(s) prior to shipment and are based on established list prices or, in the case of certain third-party insurers, contractually agreed upon prices. Provisions for discounts and rebates to customers are established as a reduction to revenue in the same period the related sales are recorded.

The Company offers a 45-day right of return for its OmniPod System sales to new patients and defers revenue to reflect estimated sales returns in the same period that the related product sales are recorded. Returns are estimated through a comparison of the Company's historical return data to its related sales. Historical rates of return are adjusted for known or expected changes in the marketplace when appropriate. When doubt exists about reasonable assuredness of collectability from specific customers, the Company defers revenue from sales of products to those customers until payment is received.

In June 2011, the Company entered into a development agreement with a U.S. based pharmaceutical company (the "Development Agreement"). Under the Development Agreement, the Company was required to perform design, development, regulatory, and other services to support the pharmaceutical company as it worked to obtain regulatory



approval to use the Company's drug delivery technology as a delivery method for its pharmaceutical. Over the term of the Development Agreement, the Company has invoiced amounts based upon

7

---

Table of Contents

meeting certain deliverable milestones. Revenue on the Development Agreement was recognized using a proportional performance methodology based on efforts incurred and total payments under the agreement. The impact of changes in the expected total effort or contract payments was recognized as a change in estimate using the cumulative catch-up method. The pharmaceutical company received regulatory approval and now purchases product from the Company for use with its pharmaceutical under a supply agreement. Product revenue under this arrangement is recognized at the time that all of the revenue recognition criteria are met, typically upon shipment.

The Company deferred revenue of \$2.3 million and \$1.6 million as of June 30, 2015 and December 31, 2014, respectively. Deferred revenue as of June 30, 2015 included \$0.2 million classified in other long term liabilities. International OmniPod revenue accounted for approximately 10% and 8% of total revenue in the second quarter and first six months of 2015, respectively, compared to approximately 16% and 17%, respectively, for the same periods in 2014.

**Shipping and Handling Costs**

The Company does not typically charge its customers for shipping and handling costs associated with shipping its product to its customers. These shipping and handling costs are included in general and administrative expenses.

**Concentration of Credit Risk**

Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains the majority of its cash with two financial institutions.

The Company purchases complete OmniPods from Flextronics International Ltd., its single source supplier. As of June 30, 2015 and December 31, 2014, liabilities from this vendor represented approximately 31% and 24% of the combined balance of accounts payable, accrued expenses and other current liabilities, respectively.

In the three months ended June 30, 2015 and 2014, two customers represented 11% and 10%, and 14% and 13% of total revenue, respectively. In the six months ended June 30, 2015, one customer represented 10% of total revenue. In the six months ended June 30, 2014, two customers represented 15% and 13% of total revenue, respectively.

**Segment Reporting**

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company's current product offering primarily consists of diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The Company's current product offering is marketed to a single customer type. As the Company sells a single product type, management operates the business as a single entity.

**Recent Accounting Pronouncements Not Yet Adopted**

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 requires that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Under this guidance, a company may make additional estimates regarding performance conditions and the allocation of variable consideration. The guidance is effective in fiscal years beginning after January 1, 2018, with early adoption permitted. The Company is currently evaluating the impact of ASU 2014-09. The Company has not yet selected a transition method nor has it determined the effect of the standard on our consolidated financial position and results of operations.

In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718), Accounting for Share-Based Payments when the terms of an award provide that a performance target could be achieved after the requisite service period ("ASU 2014-12"). ASU 2014-12 clarifies the period over which compensation cost would be recognized in awards with a performance target that affects vesting and that could be achieved after the requisite service period. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective in fiscal years beginning after January 1, 2016, with early adoption permitted. The Company is currently evaluating the impact of ASU 2014-12.

In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"). ASU 2015-03 amends existing guidance to require the presentation of debt issuance costs in the balance

sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge.

8

---

Table of Contents

The guidance is effective for annual reporting periods beginning after December 15, 2015, and must be applied retrospectively. Early adoption is permitted. Had the Company adopted ASU 2015-03, other noncurrent assets and long-term debt would both have been \$4.4 million and \$5.0 million lower as of June 30, 2015 and December 31, 2014, respectively.

In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory ("ASU 2015-11"). ASU 2015-11 amends existing guidance and requires entities to measure most inventory at the lower of cost and net realizable value. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. Upon adoption, entities must disclose the nature of and reason for the accounting change. The Company is currently evaluating the impact of ASU 2015-11.

Other Significant Policies:

The following table identifies the Company's other significant accounting policies and the note and page where a detailed description of each policy can be found.

<u>Fair Value Measurements</u>	Note	3	Page	<u>9</u>
<u>Accounts Receivable and Allowance for Doubtful Accounts</u>	Note	7	Page	<u>14</u>
<u>Inventories</u>	Note	8	Page	<u>14</u>
<u>Intangibles and Other Long-Lived Assets</u>	Note	9	Page	<u>15</u>
<u>Warranty</u>	Note	10	Page	<u>16</u>
<u>Stock-Based Compensation</u>	Note	12	Page	<u>18</u>
<u>Income Taxes</u>	Note	13	Page	<u>20</u>

Note 3. Fair Value Measurements

The Company adopted the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures ("ASC 820") related to the fair value measurement of certain of its assets and liabilities. ASC 820 defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following approaches:

- Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

- Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.

- Income approach, which is based on the present value of the future stream of net cash flows.

To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, as described in ASC 820, of which the first two are considered observable and the last unobservable:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — observable inputs other than quoted prices in active markets for identical assets or liabilities

Level 3 — unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions

The assets and liabilities subject to fair value measurement standards at June 30, 2015 and December 31, 2014 are cash equivalents, consisting of money market funds, and long-term debt which are both based on Level 1 inputs.

Certain of the Company's financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities are carried at cost, which approximates their fair value because of the

short-term maturity of these financial instruments.

9

---

Table of Contents

The following table provides a summary of financial assets that are measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands):

	Fair Value Measurements			
	Total	Level 1	Level 2	Level 3
June 30, 2015				
Cash Equivalents - Money Market Funds	\$ 108,177	\$ 108,177	\$—	\$—
December 31, 2014				
Cash Equivalents - Money Market Funds	\$ 123,141	\$ 123,141	\$—	\$—

**Debt**

The estimated fair value of debt is based on the Level 1 quoted market prices for the same or similar issues and included the impact of the conversion features.

The carrying amounts and the estimated fair values of financial instruments as of June 30, 2015 and December 31, 2014, are as follows (in thousands):

	June 30, 2015		December 31, 2014	
	Carrying Value	Estimated Fair Value	Carrying Value	Estimated Fair Value
2% Convertible Senior Notes	\$ 172,220	\$ 195,133	\$ 168,994	\$ 237,475

The Company issued \$201.3 million in principal amount of 2% Notes (as defined below) in June 2014. The carrying value of the 2% Notes at June 30, 2015 includes a debt discount of \$29.0 million which is being amortized as non-cash interest expense over the term of the 2% Notes. The decrease in the estimated fair values of these liabilities from December 31, 2014 to June 30, 2015 represents the impact of the quoted bond prices at those dates.

**Note 4. Debt**

The Company had outstanding convertible debt and related deferred financing costs on its consolidated balance sheet as follows (in thousands):

	As of	
	June 30, 2015	December 31, 2014
Principal amount of the 2% Convertible Senior Notes	\$ 201,250	\$ 201,250
Unamortized debt discount	(29,030)	(32,256)
Long-term debt, net of discount	\$ 172,220	\$ 168,994
Deferred financing costs	\$ 4,411	\$ 4,974

Interest expense related to the 3.75% Notes (as defined below) and the 2% Notes was included in interest and other expense on the consolidated statements of operations as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2015	2014	2015	2014
Contractual coupon interest	\$ 1,006	\$ 1,273	\$ 2,012	\$ 2,621
Accretion of debt discount	1,625	2,258	3,226	4,883
Amortization of debt issuance costs	281	192	563	338
Loss on extinguishment of long-term debt	—	18,943	—	18,943
Total interest and other expense	\$ 2,912	\$ 22,666	\$ 5,801	\$ 26,785

Table of Contents**3.75% Convertible Senior Notes**

In June 2011, the Company sold \$143.8 million in principal amount of 3.75% Convertible Senior Notes due June 15, 2016 (the "3.75% Notes"). The interest rate on the notes was 3.75% per annum, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 3.75% Notes were convertible into the Company's common stock at an initial conversion rate of 38.1749 shares of common stock per \$1,000 principal amount of the 3.75% Notes, which was equivalent to a conversion price of approximately \$26.20 per share.

In connection with the issuance of the 3.75% Notes, the Company repurchased \$70 million in principal amount of its 5.375% Convertible Senior Notes due June 15, 2013 (the "5.375% Notes") for \$85.1 million, a 21.5% premium on the principal amount. The investors that held the \$70 million in principal amount of repurchased 5.375% Notes purchased \$59.5 million in principal amount of the 3.75% Notes and retained approximately \$13.5 million in principal amount of the remaining 5.375% Notes. These investors' combined \$73.0 million in principal amount of convertible debt (\$13.5 million of 5.375% Notes and \$59.5 million of 3.75% Notes) was considered to be a modification of a portion of the 5.375% Notes and was accounted for separately from the issuance of the remainder of the 3.75% Notes.

The Company recorded a total debt discount of \$25.8 million related to the modified debt. This discount consisted of \$10.5 million related to the remaining debt discount on the \$70 million in principal amount of 5.375% Notes repurchased, \$15.1 million related to the premium payment in connection with the repurchase and \$0.2 million related to the increase in the value of the conversion feature. The total debt discount was being amortized as non-cash interest expense at the effective rate of 16.5% over the five year term of the modified debt. Additionally, the Company paid transaction fees of approximately \$2.0 million related to the modification, which were recorded as interest and other expense at the time of the modification.

As of December 31, 2013, the 5.375% Notes were repaid in full and no amounts remained on the Company's balance sheet related to these notes.

Of the \$143.8 million in principal amount of 3.75% Notes issued in June 2011, \$84.3 million in principal amount was considered to be an issuance of new debt. The Company recorded a debt discount of \$26.6 million related to the \$84.3 million in principal amount of 3.75% Notes. The debt discount was recorded as additional paid-in capital to reflect the value of its nonconvertible debt borrowing rate of 12.4% per annum and was being amortized as non-cash interest expense over the five year term of the 3.75% Notes. The Company incurred deferred financing costs related to this offering of approximately \$2.8 million, of which \$0.9 million has been reclassified as an offset to the value of the amount allocated to equity. The remainder was recorded as other assets in the consolidated balance sheet and was being amortized as non-cash interest expense over the five year term of the 3.75% Notes.

In June 2014, in connection with the issuance of \$201.3 million in principal amount of 2% Convertible Senior Notes due June 15, 2019 (the "2% Notes"), the Company repurchased approximately \$114.9 million in principal amount of the 3.75% Notes for \$160.7 million, a premium of \$45.8 million over the principal amount. Investors that held approximately \$80.0 million of 3.75% Notes purchased approximately \$98.2 million in principal amount of the 2% Notes. The repurchase of the 3.75% Notes was treated as an extinguishment of debt since the fair value of the conversion feature changed by more than 10%. The extinguishment of the 3.75% Notes was accounted for separately from the issuance of the 2% Notes. The \$160.7 million paid to extinguish the debt was allocated to debt and equity based on their respective fair values immediately prior to the transaction. The Company allocated \$112.4 million of the payment to the debt and \$48.3 million to equity.

The 3.75% Notes were convertible at the option of the holder during the quarter ended June 30, 2014 since the last reported sales price per share of the Company's common stock was equal to or greater than 130% of the conversion price for at least 20 of the 30 trading days ended on March 31, 2014. The 3.75% Notes and any unpaid interest were convertible at the Company's option for cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock.

Beginning on June 20, 2014, the Company had the right to redeem the 3.75% Notes, at its option, in whole or in part, if the last reported sale price per share of the Company's common stock was at least 130% of the conversion price then in effect for at least 20 trading days during a period of 30 consecutive trading days. In June 2014, the Company met the redemption requirements and notified holders of its intent to redeem the outstanding \$28.8 million in principal amount of 3.75% Notes in July 2014. Prior to the redemption date, holders of \$28.5 million in principal amount of

3.75% Notes exercised their right to convert their outstanding 3.75% Notes. The Company settled this conversion of the 3.75% Notes in July 2014 by providing cash of \$28.5 million for the principal amount of the outstanding 3.75% Notes converted and issuing 348,535 shares of common stock for the conversion premium totaling \$12.6 million, for a total consideration paid of \$41.1 million. The Company settled the redemption of the remaining \$0.3 million in principal amount in exchange for a cash payment of \$0.3 million representing



Table of Contents

principal and accrued and unpaid interest. The Company allocated \$27.9 million of the total consideration paid to the debt and \$13.5 million to equity.

The Company recorded a loss on extinguishment of debt of \$23.2 million in connection with the repurchase and redemption of the 3.75% Notes during the year ended December 31, 2014, representing the excess of the \$140.3 million allocated to the debt over its carrying value, net of deferred financing costs.

Certain features related to a portion of the 3.75% Notes, including the holders' ability to require the Company to repurchase their notes and the higher interest payments required in an event of default, were considered embedded derivatives and were required to be bifurcated and accounted for at fair value. The Company assessed the value of these embedded derivatives at each balance sheet date.

No cash interest expense was recorded related to the 3.75% Notes in the three and six months ended June 30, 2015, compared to \$1.1 million and \$2.4 million in the three and six months ended June 30, 2014, respectively. There was no non-cash interest expense recorded in the three and six months ended June 30, 2015 related to the 3.75% Notes, compared to \$2.1 million and \$4.9 million, respectively, for the corresponding periods in 2014.

As of December 31, 2014, no amounts remain outstanding related to the 3.75% Notes.

**2% Convertible Senior Notes**

In June 2014, the Company sold \$201.3 million in principal amount of the 2% Notes due June 15, 2019. The interest rate on the notes is 2% per annum, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 2% Notes are convertible into the Company's common stock at an initial conversion rate of 21.5019 shares of common stock per \$1,000 principal amount of the 2% Notes, which is equivalent to a conversion price of approximately \$46.51 per share, subject to adjustment under certain circumstances.

The Company recorded a debt discount of \$35.6 million related to the 2% Notes. The debt discount was recorded as additional paid-in capital to reflect the value of the Company's nonconvertible debt borrowing rate of 6.2% per annum. This debt discount is being amortized as non-cash interest expense over the five year term of the 2% Notes. The Company incurred deferred financing costs related to this offering of approximately \$6.7 million, of which \$1.2 million has been reclassified as an offset to the value of the amount allocated to equity. The remainder is recorded as other assets in the consolidated balance sheet and is being amortized as non-cash interest expense over the five year term of the 2% Notes.

The Company determined that the higher interest and tax payments required in certain circumstances are considered embedded derivatives and should be bifurcated and accounted for at fair value. The Company assesses the value of the embedded derivatives at each balance sheet date. The derivatives had de minimis value at the balance sheet date.

Cash interest expense related to the 2% Notes was \$1.0 million and \$0.2 million in the three months ended June 30, 2015 and 2014, respectively, and \$2.0 million and \$0.2 million in the six months ended June 30, 2015 and 2014, respectively. Non-cash interest expense related to the 2% Notes was \$1.9 million and \$0.3 million in the three months ended June 30, 2015 and 2014, respectively, and \$3.8 million and \$0.3 million in the six months ended June 30, 2015 and 2014, respectively.

As of June 30, 2015, the Company included \$172.2 million on its balance sheet in long-term debt related to the 2% Notes.

Table of Contents

## Note 5. Capital Lease Obligations

As of June 30, 2015 and December 31, 2014, the Company has approximately \$13.7 million and \$8.0 million of manufacturing equipment acquired under capital leases, respectively. The obligations under the capital leases are being repaid in equal monthly installments over 24 to 36 month terms and include principal and interest payments with an effective interest rate of 13% to 17%.

The assets have been recorded at \$13.7 million and are included in property and equipment on the Company's balance sheet as of June 30, 2015. The assets acquired under capital leases are being amortized on a straight-line basis over 5 years in accordance with the Company's policy for depreciation of manufacturing equipment. Amortization expense on assets acquired under capital leases is included with depreciation expense. Amortization expense related to these capital leased assets was \$0.6 million and \$0.4 million in the three months ended June 30, 2015 and 2014, respectively, and \$1.1 million and \$0.7 million in the six months ended June 30, 2015 and 2014, respectively.

Assets held under capital leases consist of the following (in thousands):

	As of	
	June 30, 2015	December 31, 2014
Manufacturing equipment	\$13,705	\$7,984
Less: Accumulated amortization	(3,012	) (1,885
Total	\$10,693	\$6,099

The aggregate future minimum lease payments related to these capital leases as of June 30, 2015, are as follows (in thousands):

Years Ending December 31,	Minimum Lease Payments
2015 (remaining)	\$3,524
2016	5,639
2017	269
Total future minimum lease payments	\$9,432
Interest expense	(882
Total capital lease obligations	\$8,550

The Company recorded \$0.4 million and \$0.3 million of interest expense on the capital leases in the three months ended June 30, 2015 and 2014, respectively. The Company recorded \$0.7 million and \$0.6 million in the six months ended June 30, 2015 and 2014, respectively.

Table of Contents

## Note 6. Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, excluding unvested restricted common shares. Diluted net loss per share is computed using the weighted average number of common shares outstanding and, when dilutive, potential common share equivalents from options, restricted stock units and warrants (using the treasury-stock method), and potential common shares from convertible securities (using the if-converted method). Because the Company reported a net loss for the three and six months ended June 30, 2015 and 2014, all potential dilutive common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive.

Potential dilutive common share equivalents consist of the following:

	Three and Six Months Ended June 30,	
	2015	2014
3.75% Convertible Senior Notes	—	1,100,811
2.00% Convertible Senior Notes	4,327,257	4,327,257
Unvested restricted stock units	948,554	968,083
Outstanding options	2,879,370	1,634,584
Total dilutive common shares	8,155,181	8,030,735

## Note 7. Accounts Receivable

Accounts receivable consist of amounts due from third-party payors, patients, third-party distributors and government agencies. The Company records an allowance for doubtful accounts at the time potential collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risk, discussions with individual customers or various assumptions and estimates that are believed to be reasonable under the circumstances. The Company believes the reserve is adequate to mitigate current collection risk.

Accounts receivable from one customer represented 14% of gross accounts receivable as of June 30, 2015. As of December 31, 2014 accounts receivable from two customers represented approximately 19% and 10% of gross accounts receivable, respectively.

The components of accounts receivable are as follows (in thousands):

	As of	
	June 30, 2015	December 31, 2014
Trade receivables	\$37,162	\$45,719
Allowance for doubtful accounts	(5,336	) (5,837
Total accounts receivable	\$31,826	\$39,882

## Note 8. Inventories

Inventories are held at the lower of cost or market, determined under the first-in, first-out method. Inventory has been recorded at cost as of June 30, 2015 and December 31, 2014. Work in process is calculated based upon a buildup in the stage of completion using estimated labor inputs for each stage in production. The Company periodically reviews inventories for net realizable value based on quantities on hand and expectations of future use.

Inventories consist of the following (in thousands):

	As of	
	June 30, 2015	December 31, 2014
Raw materials	\$1,465	\$853
Work-in-process	2,245	254
Finished goods, net	19,725	11,992
Total inventories	\$23,435	\$13,099

Table of Contents

## Note 9. Other Intangible Assets

The Company's finite-lived intangible assets are stated at cost less accumulated amortization. The Company assesses its intangible and other long-lived assets for impairment whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company recognizes an impairment loss for intangibles and other finite-lived assets if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Any such impairment loss is measured as the difference between the carrying amount and the fair value of the asset. The estimation of useful lives and expected cash flows requires the Company to make significant judgments regarding future periods that are subject to some factors outside its control. Changes in these estimates can result in significant revisions to the carrying value of these assets and may result in material charges to the results of operations. The Company recorded \$32.9 million of other intangible assets as a result of the acquisition of Neighborhood Diabetes. The estimated life of the acquired tradename asset is 15 years. The estimated useful life of the acquired customer relationship asset is 10 years. Intangible assets with determinable estimated lives are amortized over these lives.

Other intangible assets consist of the following (in thousands):

	As of June 30, 2015			December 31, 2014		
	Cost	Accumulated Amortization	Net Book Value	Cost	Accumulated Amortization	Net Book Value
Customer relationships	\$30,100	\$(19,837 )	\$10,263	\$30,100	\$(18,167 )	\$11,933
Tradename	2,800	(762 )	2,038	2,800	(669 )	2,131
Total intangible assets	\$32,900	\$(20,599 )	\$12,301	\$32,900	\$(18,836 )	\$14,064

Amortization expense related to other intangible assets was approximately \$0.9 million and \$1.1 million for the three months ended June 30, 2015 and 2014, respectively. Amortization expense was approximately \$1.8 million and \$2.2 million for the six months ended June 30, 2015 and 2014, respectively.

Amortization expense expected for the next five years and thereafter is as follows (in thousands):

Years Ending December 31,	Amortization Expense		
	Customer Relationships	Tradename	Total
2015 (remaining)	\$1,394	\$94	\$1,488
2016	2,478	187	2,665
2017	2,003	187	2,190
2018	1,619	187	1,806
2019	1,309	187	1,496
Thereafter	1,460	1,196	2,656
Total	\$10,263	\$2,038	\$12,301

As of June 30, 2015, the weighted average amortization period of the Company's intangible assets is approximately 7 years.

Table of Contents

## Note 10. Product Warranty Costs

The Company provides a four-year warranty on its PDMs and may replace any OmniPods that do not function in accordance with product specifications. The Company estimates its warranty at the time the product is shipped based on historical experience and the estimated cost to service the claims. Cost to service the claims reflects the current product cost which has been decreasing over time. As these estimates are based on historical experience, and the Company continues to introduce new products and versions, the Company also considers the anticipated performance of the product over its warranty period in estimating warranty reserves.

A reconciliation of the changes in the Company's product warranty liability is as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2015	2014	2015	2014
Balance at the beginning of the period	\$2,661	\$3,100	\$2,614	\$3,090
Warranty expense <sup>(1)</sup>	1,254	(150)	) 1,721	542
Warranty claims settled	(748	) (445	) (1,168	) (1,127
Balance at the end of the period	\$3,167	\$2,505	\$3,167	\$2,505

Includes an additional reserve estimate of \$0.2 million relating to the expected product replacement costs from the

<sup>(1)</sup> Company's voluntary recall of certain lots of OmniPods in response to the warning letter received from the U.S. Food and Drug Administration (FDA) for the three and six months ending June 30, 2015.

	As of	
	June 30,	December 31,
	2015	2014
Composition of balance:		
Short-term	\$1,566	\$981
Long-term	1,601	1,633
	\$3,167	\$2,614

## Note 11. Commitments and Contingencies

## Operating Leases

The Company leases its facilities in Massachusetts, New York, Florida, Canada and Singapore. The Company's leases are accounted for as operating leases. The leases generally provide for a base rent plus real estate taxes and certain operating expenses related to the leases.

In 2013, the Company entered into a new lease agreement for approximately 90,000 square feet of laboratory and office space for its corporate headquarters in Billerica, Massachusetts. The lease term began in August 2014 and expires in October 2022 and contains escalating payments over the life of the lease. In 2015, the Company extended its Singapore lease which now expires in July 2016. In 2014, the Company amended its existing lease for warehouse space in Billerica, Massachusetts which extended the term and increased the approximate square footage under the lease. The lease now expires in September 2019. Additionally, in 2014, the Company amended its existing lease for office space in New York which now expires in January 2019. The Company's Florida lease expires in December 2015. In the second quarter of 2015, the Company entered into a new lease agreement of office space in Ontario, Canada. The lease term began in June 2015 and expires in May 2018.

Certain of the Company's operating lease agreements contain scheduled rent increases. Rent expense is recorded using the straight-line method and deferred rent is included in other liabilities in the accompanying balance sheets. The Company has considered FASB ASC 840-20, Leases in accounting for these lease provisions.



Table of Contents

The aggregate future minimum lease payments related to these leases as of June 30, 2015, are as follows (in thousands):

Years Ending December 31,	Minimum Lease Payments
2015 (remaining)	\$1,154
2016	2,290
2017	2,327
2018	2,308
2019	2,181
Thereafter	6,080
Total	\$16,340

Legal Proceedings

In October 2013, the Company received a letter from the Office of the Massachusetts Attorney General contending that prior to September 2012 Neighborhood Diabetes engaged in improper sales practices by automatically refilling certain prescriptions for MassHealth patients. The Company responded to this letter, stating that Neighborhood Diabetes' refill practices during the period in question were appropriate and consistent with applicable laws. The Company entered into a Settlement and Release Agreement and paid approximately \$1.5 million in connection with the settlement of this matter in the first quarter of 2015.

The Company has replied and is currently awaiting a response in relation to a letter of preliminary audit results received in April 2015 on behalf of the Centers for Medicare and Medicaid Services and the State of New York alleging overpayment of certain Medicaid claims to Neighborhood Diabetes. The Company believes the likelihood of a loss is reasonably possible. However, due to the preliminary nature of this matter, the Company is not able to assess its ultimate outcome, or reasonably estimate a range of possible loss.

The Company is in the process of responding to a letter of preliminary audit results received in June 2015 from the Connecticut Department of Social Services Office of Quality Assurance alleging overpayment of certain Medicaid claims to Neighborhood Diabetes. Due to the preliminary nature of this matter, the Company is not able to assess its ultimate outcome, or reasonably estimate a range of possible loss.

The Company received a warning letter from the FDA in June 2015 that related to the release of certain lots of OmniPods that did not conform to final acceptance criteria. A voluntary recall of the identified lots was issued and a range of potential product replacement costs associated with the recall was estimated between \$0.2 million and \$0.4 million. As the Company is not able to assess the exact liability, \$0.2 million was recorded to warranty expense in the second quarter of 2015. The Company has replied to the FDA's letter, and received a response indicating that its corrective actions appear to have adequately addressed the issue outlined in the letter.

The Company has reached a settlement agreement with the Massachusetts Department of Revenue for sales and use tax audits related to Neighborhood Diabetes. Based on the settlement agreement, the Company recorded a liability of \$0.8 million, which was a reduction of its previously recorded liability of \$3.7 million in connection with the settlement of this matter at June 30, 2015.

On May 5, 2015-June 16, 2015, three class action lawsuits were filed by shareholders in the U.S. District Court, Massachusetts, against the Company and certain individual current and former executives of the Company. Two suits were voluntarily dismissed. Arkansas Teacher Retirement System v. Insulet, et al., 1:15-cv-12345, alleges violations of Sections 10(b) and 20(a) and Rule 10b-5 of the Securities Exchange Act of 1934 by making allegedly false and misleading statements about the Company's business, operations, and prospects. The lawsuit seeks, among other things, compensatory damages in connection with the Company's allegedly inflated stock price between May 7, 2013 and April 30, 2015, as well as attorneys' fees and costs. In light of the preliminary nature of this matter, the Company is unable to reasonably assess its ultimate outcome. However, the Company believes that the resolution of this matter will not have a material adverse effect on its financial condition.

The Company is, from time to time, involved in the normal course of business in various legal proceedings, including intellectual property, contract employment and product liability suits. Although the Company is unable to quantify the exact financial impact of any of these matters, the Company believes that none of these currently pending matters will

have an outcome material to its financial condition or business.



## Table of Contents

### Indemnifications

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.

In accordance with its bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company's request in such capacity. There have been no claims to date under such indemnification obligations and the Company has a director and officer insurance policy that enables it to recover a portion of any amounts paid for future claims.

Under the Merger Agreement with Neighborhood Diabetes, the Company was indemnified by the former stockholders of Neighborhood Diabetes for any liability resulting from or related to any tax attributable to pre-acquisition periods. In August 2014, the Company entered into a Settlement Agreement with the former stockholders of Neighborhood Diabetes related to certain indemnified items. Amounts received by the Company under the Settlement Agreement were recorded as an offset to expenses in 2014.

### Note 12. Equity

The Company accounts for stock-based compensation under the provisions of FASB ASC 718-10, Compensation — Stock Compensation ("ASC 718-10"), which requires all share-based payments to employees, including grants of employee stock options and restricted stock units, to be recognized in the income statement based on their fair values. Share-based payments that contain performance conditions are recognized when such conditions are probable of being achieved.

The Company uses the Black-Scholes option pricing model to determine the weighted-average fair value of options granted. The Company determines the intrinsic value of restricted stock and restricted stock units based on the closing price of its common stock on the date of grant. The Company recognizes the compensation expense of share-based awards on a straight-line basis for awards with only service conditions and on an accelerated method for awards with performance conditions. Compensation expense is recognized over the vesting period of the awards.

The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life of the awards is estimated based on the midpoint scenario, which combines historical exercise data with hypothetical exercise data for outstanding options. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on Company history and expectation of paying no dividends. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. The Company evaluates the assumptions used to value the awards on a quarterly basis and if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense.

In July 2014, in connection with the extinguishment of \$28.5 million in principal amount of 3.75% Notes, the Company issued 348,535 shares of its common stock to the holders representing the conversion premium.

The Company grants share-based awards to employees in the form of options to purchase the Company's common stock, the ability to purchase stock at a discounted price under the employee stock purchase plan and restricted stock units. Stock-based compensation expense related to share-based awards recognized in the three month periods ended June 30, 2015 and 2014 was \$4.3 million and \$4.2 million, respectively, and was calculated based on awards ultimately expected to vest. Stock-based compensation expense related to share-based awards recognized in the six month periods ended June 30, 2015 and 2014 was \$9.6 million and \$8.6 million, respectively, and was calculated on awards ultimately expected to vest.

At June 30, 2015, the Company had \$50.3 million of total unrecognized compensation expense related to unvested stock options and restricted stock units.

18

---

Table of Contents

## Stock Options

In May 2007, in conjunction with the Company's initial public offering, the Company adopted its 2007 Stock Option and Incentive Plan (the "2007 Plan"). The 2007 Plan was amended and restated in November 2008, May 2012 and May 2015 to provide for the issuance of additional shares and to amend certain other provisions. As of June 30, 2015, 841,750 shares remain available for future issuance under the 2007 Plan.

In the six months ended June 30, 2015, the Company awarded 184,500 shares of performance-based incentive stock options. The stock options were granted under the 2007 Plan and vest over a four year period from the grant date with the potential of an accelerated vesting period pursuant to the achievement of certain performance conditions.

The following summarizes the activity under the Company's stock option plans:

	Number of Options (#)	Weighted Average Exercise Price (\$)	Aggregate Intrinsic Value (\$) (In thousands)
Balance, December 31, 2014	1,847,669	\$26.99	
Granted	1,555,866	32.98	
Exercised <sup>(1)</sup>	(398,745 )	15.62	\$7,922
Canceled	(125,420 )	30.16	
Balance, June 30, 2015	2,879,370	\$31.66	\$8,262
Vested, June 30, 2015 <sup>(2)</sup>	869,820	\$27.05	\$6,428
Vested and expected to vest, June 30, 2015 <sup>(2)(3)</sup>	2,589,255		\$8,039

(1) The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company's common stock as of the date of exercise and the exercise price of the underlying options.

(2) The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company's common stock as of June 30, 2015, and the exercise price of the underlying options.

Represents the number of vested options as of June 30, 2015, plus the number of unvested options expected to vest

(3) as of June 30, 2015, based on the unvested options outstanding at June 30, 2015, adjusted for the estimated forfeiture.

At June 30, 2015 there were 2,879,370 options outstanding with a weighted average exercise price of \$31.66 and a weighted average remaining contractual life of 8.4 years. At June 30, 2015 there were 869,820 options exercisable with a weighted average exercise price of \$27.05 and a weighted average remaining contractual life of 6.7 years.

Employee stock-based compensation expense related to stock options in the three month periods ended June 30, 2015 and 2014 was \$2.0 million and \$1.3 million, respectively, and was based on awards ultimately expected to vest.

Employee stock-based compensation expense related to stock options in the six months ended June 30, 2015 and 2014 was \$5.0 million and \$2.9 million, respectively, and was based on awards ultimately expected to vest. At June 30, 2015, the Company had \$23.0 million of total unrecognized compensation expense related to stock options that will be recognized over a weighted average period of 1.4 years.

## Employee Stock Purchase Plan

As of June 30, 2015 the Company had 9,713 shares contingently issued under the employee stock purchase plan ("ESPP"). As of June 30, 2014, the Company had 6,898 shares contingently issued under the ESPP. In the three and six months ended June 30, 2015 and 2014, the Company recorded no significant stock-based compensation charges related to the ESPP.

## Restricted Stock Units

In the six months ended June 30, 2015, the Company awarded 635,781 restricted stock units to certain employees, which included 114,287 restricted stock units subject to the achievement of performance conditions (performance-based restricted stock units). The number of performance-based restricted stock units granted during the six months ended June 30, 2015 that are expected to vest may vary based on the Company's quarterly evaluation of the probability of the performance criteria being achieved. The Company did not recognize stock compensation expense in the six months ended 2015 as it does not expect that any of the performance-based restricted stock units

granted will be earned based on its evaluation of the performance criteria at June 30, 2015. The restricted stock units were granted under the 2007 Plan and vest annually over a three year period from the grant date.

Table of Contents

The restricted stock units granted have a weighted average fair value of \$32.55 per share based on the closing price of the Company's common stock on the date of grant. The restricted stock units granted during the six months ended June 30, 2015 were valued at approximately \$20.7 million on their grant date, and the Company is recognizing the compensation expense over the vesting period. Approximately \$2.3 million and \$2.9 million of stock compensation expense related to the vesting of restricted stock units was recognized in the three months ended June 30, 2015 and 2014, respectively. Approximately \$4.6 million and \$5.7 million of stock-based compensation expense related to the vesting of restricted stock units was recognized in the six months ended June 30, 2015 and 2014, respectively. Approximately \$27.3 million of the fair value of the restricted stock units remained unrecognized as of June 30, 2015 and will be recognized over a weighted average period of 1.5 years. Under the terms of the awards, the Company will issue shares of common stock on each of the vesting dates.

The following table summarizes the status of the Company's restricted stock units:

	Number of Shares (#)	Weighted Average Fair Value (\$)
Balance, December 31, 2014	746,612	\$31.40
Granted	635,781	32.55
Vested	(247,855	) 28.27
Forfeited	(185,984	) 32.67
Balance, June 30, 2015	948,554	\$32.73

## Note 13. Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect in the years in which the differences are expected to reverse. A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, and the expected timing of the reversals of existing temporary differences and tax planning strategies. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company follows the provisions of FASB ASC 740-10, Income Taxes ("ASC 740-10") on accounting for uncertainty in income taxes recognized in its financial statements. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In addition, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company recognizes estimated interest and penalties for uncertain tax positions in income tax expense.

The Company files federal, state and foreign tax returns. These returns are generally open to examination by the relevant tax authorities from three to four years from the date they are filed. The tax filings relating to the Company's federal and state tax returns are currently open to examination for tax years 2011 through 2013 and 2010 through 2013, respectively. In addition, the Company has generated tax losses since its inception in 2000. These years may be subject to examination if the losses are carried forward and utilized in future years.

At June 30, 2015 and December 31, 2014, the Company provided a valuation allowance for the full amount of its net deferred tax asset because it is not more likely than not that the future tax benefit will be realized.

Income tax expense consists of the following (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2015	2014	2015	2014
Current	\$ 16	\$ 22	\$ 40	\$ 53
Deferred	21	30	49	64

Edgar Filing: INSULET CORP - Form 10-Q

Total	\$37	\$52	\$89	\$117
-------	------	------	------	-------

20

---

Table of Contents

In the three and six months ended June 30, 2015 and 2014, the current portion of income tax expense primarily related to state and foreign taxes, and the deferred portion primarily related to U.S. Federal and State amounts.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes as well as federal and state net operating losses and tax credit carryforwards.

In the future, the Company will generate additional deferred tax assets and liabilities related to its amortization of acquired intangible assets for tax purposes because these long-lived intangible assets are not amortized for financial reporting purposes. The tax amortization in future years will give rise to a temporary difference and a tax liability, which will only reverse at the time of ultimate sale or further impairment of the underlying intangible assets. Due to the uncertain timing of this reversal, the temporary difference cannot be considered as a source of future taxable income for purposes of determining a valuation allowance; therefore, the tax liability cannot be used to offset the deferred tax asset related to the net operating loss carryforward for tax purposes that will be generated by the same amortization.

The Company had no unrecognized tax benefits at June 30, 2015.

Note 14. Subsequent Events

On July 7, 2015, pursuant to an agreement with GlaxoSmithKline (GSK), the Company acquired the OmniPod distribution business in Canada for approximately \$5 million.

Note 15. Change in Accounting Estimate

The Company capitalizes eligible software development costs, including salaries and payroll-related costs of employees who devote time to the development. Capitalization begins when a detail program design is completed and technological feasibility has been established. These costs are amortized on a straight-line basis over the estimated useful life. In the second quarter of 2015, based on changes in one of the Company's ongoing projects, the Company determined that the detailed program designs were no longer sufficiently complete to establish technological feasibility of this project. As such, all costs previously capitalized for this project, approximately \$1.3 million, and all subsequent costs incurred through June 30, 2015, have been recorded to research and development expense during the current period. This change in estimate increased research and development expense in the three and six months ended June 30, 2015 by approximately \$4.7 million.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

You should read the following discussion of our financial condition and results of operations in conjunction with our consolidated financial statements and the accompanying condensed notes to those financial statements included in this Quarterly Report on Form 10-Q. This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, but are not limited to:

- risks associated with our dependence on our principal product, the OmniPod System;
- our ability to sustain or reduce production costs and increase customer orders and manufacturing volumes;
- adverse changes in general economic conditions;
- impact of healthcare reform laws;
- our inability to raise additional funds in the future on acceptable terms or at all;
- potential supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent;
- the potential establishment of a competitive bid program;
- failure to retain supplier pricing discounts and achieve satisfactory gross margins;
- failure to retain key supplier and payor partners;
- international business risks;
- our inability to secure and retain adequate coverage or reimbursement for the OmniPod System by third-party payors and potential adverse changes in reimbursement rates or policies relating to the OmniPod System;
- failure to retain key payor partners and their members;
- failure to retain and manage successfully our Medicare and Medicaid business;
- potential adverse effects resulting from competition;
- reliance on information technology systems and our ability to control related risks, including a cyber-attack or other breach or disruption of these systems;
- technological breakthroughs and innovations adversely affecting our business, and our own new product development initiatives may prove to be ineffective or not commercially successful;
- potential termination of our license to incorporate a blood glucose meter into the OmniPod System, or our inability to enter into new license agreements;
- challenges to the further development of our non-insulin drug delivery business;
- our ability to protect our intellectual property and other proprietary rights; conflicts with the intellectual property of third-parties, including claims that our current or future products infringe or misappropriate the proprietary rights of others;
- adverse regulatory or legal actions relating to the OmniPod System;
- failure of our contract manufacturers or component suppliers to comply with the FDA's quality system regulations;
- the potential violation of federal or state laws prohibiting "kickbacks" or protecting the confidentiality of patient health information, or any challenge to or investigation into our practices under these laws;



Table of Contents

product liability lawsuits that may be brought against us;  
reduced retention rates of our customer base;  
unfavorable results of clinical studies relating to the OmniPod System or the products of our competitors;  
potential future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable to the OmniPod System;  
the concentration of substantially all of our operations at a single location in China and substantially all of our inventory at a single location in Massachusetts;  
our ability to attract and retain personnel;  
our ability to manage our growth;  
fluctuations in quarterly results of operations;  
risks associated with potential future acquisitions or investments in new businesses;  
our ability to generate sufficient cash to service all of our indebtedness;  
the expansion of our distribution network;  
our ability to successfully maintain effective internal control over financial reporting;  
the volatility of the price of our common stock;  
risks related to future sales of our common stock or the conversion of any of our 2% Convertible Senior Notes due June 15, 2019;  
potential limitations on our ability to use our net operating loss carryforwards; and  
anti-takeover provisions in our organizational documents.

The factors discussed above are not intended to be a complete statement of all risks and uncertainties and should be evaluated with all other risks described in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 26, 2015 in the section entitled “Risk Factors,” and in our other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements.

Overview

We are primarily engaged in the development, manufacturing and sale of our proprietary OmniPod Insulin Management System (the “OmniPod System”), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (“PDM”). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to 42 inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. We believe that the OmniPod System’s unique proprietary design offers significant lifestyle benefits to people with insulin-dependent diabetes.

In June 2011, we acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, “Neighborhood Diabetes”) in order to support our sales of the OmniPod System, expand our full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, we are able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and have the ability to process claims as either durable medical equipment or through pharmacy benefits.

We began commercial sale of the OmniPod System in the United States in 2005. We sell the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through our distribution partners. The OmniPod System is currently available in multiple countries in Europe and in Canada. We have been selling our new OmniPod System since 2013. The new OmniPod System is more than one-third smaller and one-quarter lighter than the original version, while maintaining the same features and operating capabilities.



## Table of Contents

We sell our proprietary OmniPod System as well as blood glucose testing supplies, traditional insulin pumps, pump supplies, pharmaceuticals and other products for the management and treatment of diabetes to people with diabetes. Through our infrastructure in the reimbursement, billing and collection areas, we are able to provide for adjudication of claims as either durable medical equipment or through pharmacy benefits. Claims are adjudicated under private insurers, Medicaid or Medicare. As we expand our sales and marketing focus, increase our manufacturing capacity and expand to additional international markets, we will need to maintain and expand available reimbursement for our product offerings.

Our sales and marketing effort is focused on generating demand and acceptance of the OmniPod System among key diabetes practitioners, academic medical centers, clinics, people with insulin-dependent diabetes, third-party payors, government agencies, and third-party distributors. Our marketing strategy is to build awareness for the benefits of the OmniPod System through a wide range of education programs, social networking, patient demonstration programs, support materials, media advertisements and events at the national, regional and local levels. We are using third-party distributors to improve our access to managed care and government reimbursement programs, expand our commercial presence and provide access to additional potential patients. Our total revenue was \$75.6 million and \$136.8 million for the three and six months ended June 30, 2015, compared to \$72.0 million and \$141.2 million, respectively, in the corresponding 2014 periods.

We currently produce the OmniPod System on partially automated manufacturing lines at a facility in China operated by a subsidiary of Flextronics International Ltd. ("Flextronics"). We purchase complete OmniPods pursuant to our agreement with Flextronics. Under the agreement, Flextronics has agreed to supply us, as a non-exclusive supplier, with OmniPods at agreed upon prices per unit pursuant to a rolling forecast that we provide. The current term of the agreement expires in December 2017 and is automatically renewed for one-year terms subsequently. It may be terminated upon prior written notice given no less than a specified number of days prior to the date of termination. The specified number of days is intended to provide the parties with sufficient time to make alternative arrangements in the event of termination.

We seek to increase manufacturing volumes and reduce the per-unit production cost for the OmniPod. By increasing production volumes of the OmniPod, we have been able to reduce our per-unit raw material costs and improve absorption of manufacturing overhead costs. We continue to seek to sustain or reduce our cost per OmniPod through reductions in the bill of material as well as through manufacturing efficiencies. We believe our current manufacturing capacity is sufficient to meet our expected 2015 demand for OmniPods.

We purchase certain other diabetes management supplies from manufacturers at contracted rates and supply these products to our customers. Based on market penetration, payor plans and other factors, certain manufacturers provide rebates based on product sold. We record these rebates as a reduction to cost of goods sold as they are earned. Since our inception in 2000, we have incurred losses every quarter. In the three and six months ended June 30, 2015, we incurred net losses of \$15.4 million and \$27.3 million, respectively. As of June 30, 2015, we had an accumulated deficit of \$605.3 million. We have financed our operations through private placements of debt and equity securities, public offerings of our common stock, issuances of convertible debt and borrowings under certain other debt agreements. As of June 30, 2015, we had \$201.3 million of convertible debt outstanding which matures in June 2019. Our long-term financial objective is to achieve and sustain profitable growth. Our efforts in 2015 will be focused primarily on the expansion of our customer base in the United States and internationally. Achieving these objectives is expected to require additional investments in certain personnel and initiatives. We believe that we will continue to incur net losses in the near term in order to achieve these objectives. However, we believe that the accomplishment of our near term objectives will have a positive impact on our financial condition in the future.

At June 30, 2015, we had cash and cash equivalents totaling \$145.1 million. We believe that our cash and cash equivalents, together with the cash expected to be generated from product sales, will be sufficient to meet our projected operating and debt service requirements for the next twelve months.

### Financial Operations Overview

Revenue. We derive most of our revenue from the sale of the OmniPod System and other diabetes related products including blood glucose testing supplies, traditional insulin pumps, pump supplies and other pharmaceuticals to customers and third-party distributors who resell the product to customers. The OmniPod System is comprised of two

devices: the OmniPod, a disposable insulin infusion device that the patient wears for up to three days and then replaces; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions, assists the patient with diabetes management and incorporates a blood glucose meter.

Table of Contents

In June 2011, we entered into a development agreement with a U.S. based pharmaceutical company (the "Development Agreement"). Under the Development Agreement, we were required to perform design, development, regulatory, and other services to support the pharmaceutical company as it worked to obtain regulatory approval to use our drug delivery technology as a delivery method for its pharmaceutical. Over the term of the Development Agreement, we have invoiced amounts based upon meeting certain deliverable milestones. Revenue on the Development Agreement was recognized using a proportional performance methodology based on efforts incurred and total payments under the agreement. The impact of changes in the expected total effort or contract payments was recognized as a change in estimate using the cumulative catch-up method. The pharmaceutical company received regulatory approval in December 2014 and now purchases product from us for use with its pharmaceutical under a supply agreement. Product revenue under this arrangement is recognized at the time that all of the revenue recognition criteria are met, typically upon shipment.

As of June 30, 2015 and December 31, 2014, we had deferred revenue of \$2.3 million and \$1.6 million, respectively. Total deferred revenue as of June 30, 2015 included \$0.2 million classified in long term liabilities.

For the year ending December 31, 2015, we expect our revenue to continue to increase as we gain new customers in the United States; continue expansion in Europe, Canada, and certain other international markets and increase commercial sales with our drug delivery partners. Increased revenue is dependent upon the success of our sales efforts and our ability to produce OmniPods in sufficient volumes as our patient base grows and is subject to other risks and uncertainties, including the potential for a reduction in on-hand inventory levels amongst our distributors.

**Cost of revenue.** Cost of revenue consists primarily of raw material, labor, warranty, inventory reserve and overhead costs such as freight and depreciation related to the OmniPod System and the cost of products we acquire from third party suppliers. Cost of revenue will continue to increase as our revenue increases; however, we expect our gross margin to improve as our revenue mix changes and we continue to sustain or reduce our per OmniPod cost.

**Research and development.** Research and development expenses consist primarily of personnel costs within our product development, regulatory and clinical functions, and product development projects. We expense all research and development costs as incurred, unless these costs meet the criteria to be capitalized as internal use software or software to be sold, leased or marketed. For the year ending December 31, 2015, we expect overall research and development spending to increase from our 2014 spend as we increase development efforts on our on-going projects including continued improvements to the manufacturing process of the OmniPod System, the development of the new PDM, the integration with continuous glucose monitoring technology, the development of the Type 2 pump with Eli Lilly and Company and the ability to use our technology as a delivery platform for other pharmaceuticals.

**General and administrative.** General and administrative expenses consist primarily of salaries and other related costs for personnel serving the executive, finance, information technology and human resource functions, as well as legal fees, accounting fees, insurance costs, bad debt expenses, shipping, handling and facilities-related costs. For the year ending December 31, 2015, we expect general and administrative expenses to slightly increase compared to 2014 as we continue to advance our business and strengthen our management team.

**Sales and marketing.** Sales and marketing expenses consist primarily of personnel costs within our sales, marketing, reimbursement support, customer support and training functions, sales commissions paid to our sales representatives and costs associated with participation in medical conferences, physician symposia and promotional activities, including distribution of units used in our demonstration kit programs. We expect sales and marketing expenses in the year ending December 31, 2015 to increase compared to 2014 as we expand our commercial team and invest in initiatives that will enhance awareness and drive increased adoption of the OmniPod System.

Table of Contents

## Results of Operations

This section discusses our consolidated results of operations for the second quarter and first six months of 2015 compared to the same periods in 2014, and should be read in conjunction with the consolidated financial statements and accompanying condensed notes included in this Form 10-Q.

TABLE 1: RESULTS OF OPERATIONS

(In Thousands)	Three Months Ended June 30,				Six Months Ended June 30,			
	2015	2014	\$ Change	% Change	2015	2014	\$ Change	% Change
Revenue	\$75,588	\$72,013	\$3,575	5 %	\$136,803	\$141,174	\$(4,371)	(3)%
Cost of revenue	41,213	36,248	4,965	14 %	69,621	72,601	(2,980)	(4)%
Gross profit	34,375	35,765	(1,390)	(4)%	67,182	68,573	(1,391)	(2)%
Operating expenses:								
Research and development	12,069	6,677	5,392	81 %	20,276	13,456	6,820	51 %
General and administrative	12,856	19,512	(6,656)	(34)%	28,685	33,771	(5,086)	(15)%
Sales and marketing	21,811	14,856	6,955	47 %	39,212	28,512	10,700	38 %
Total operating expenses	46,736	41,045	5,691	14 %	88,173	75,739	12,434	16 %
Operating loss	(12,361)	(5,280)	7,081	134 %	(20,991)	(7,166)	13,825	193 %
Interest and other expense, net	(3,034)	(23,779)	(20,745)	(87)%	(6,186)	(27,972)	(21,786)	(78)%
Income tax expense	(37)	(52)	(15)	(29)%	(89)	(117)	(28)	(24)%
Net loss	\$(15,432)	\$(29,111)	\$(13,679)	(47)%	\$(27,266)	\$(35,255)	\$(7,989)	(23)%

## Revenue

Our total revenue increased \$3.6 million in the second quarter of 2015 compared to the second quarter of 2014, mainly due to continued adoption of the Omnipod System by patients in the United States and strong growth in commercial sales of our on-body injection devices for drug delivery.

Total revenue decreased \$4.4 million in the first six months of 2015 compared to the same period in 2014, primarily the result of lower international OmniPod revenue of approximately \$12.9 million offset in part by an increase revenue from our on-body injection devices for drug delivery of approximately \$9.9 million.

## Cost of Revenue

Cost of revenue increased \$5.0 million in the second quarter of 2015 compared to the second quarter of 2014 due to an increase in sales volumes and higher scrap and warranty charges, which together increased by \$4.4 million. In the first six months of 2015, cost of revenue decreased \$3.0 million compared to the same period in 2014, mainly due to favorable product mix offset by higher scrap and warranty charges which together increased by \$3.9 million. We recently implemented procedures with more stringent final acceptance criteria. As such, product quality is now at the highest level in our history and therefore certain product in inventory did not meet the more stringent acceptance criteria now in place. We believe approximately \$2.5 million of the incremental scrap and warranty charges in the second quarter and the first six months of 2015 were non-recurring in nature.

## Research and Development

Research and development expenses increased \$5.4 million to \$12.1 million for the three months ended June 30, 2015, compared to \$6.7 million for the same period in 2014. The increase was primarily the result of expenses related to our development projects and ongoing efforts to improve our current product, as well as expenses related to our change in estimate of software development costs of \$4.7 million.

Research and development expenses increased \$6.8 million to \$20.3 million for the six months ended June 30, 2015, compared to \$13.5 million for the same period in 2014. The increase was primarily the result of a \$5.9 million increase in expenses related to our development projects, expenses related to our change in estimate of software development costs of \$4.7 million and a \$0.8 million increase in employee related expenses, including costs related to the addition of employees and higher management transition costs.

Additional information regarding our change in accounting estimate for development costs is provided in note 15 to the consolidated financial statements included in this Form 10-Q.

## Table of Contents

### General and Administrative

General and administrative expenses decreased \$6.7 million and \$5.1 million in the second quarter and first six months of 2015, respectively, compared to the same periods in 2014. The decrease was primarily the result of the Becton Dickinson patent litigation settlement and other legal fees of approximately \$8.6 million and \$9.6 million, respectively included in 2014. The decrease also included a \$2.7 million reduction of the previously recorded liability associated with sales and use tax audits based on a final settlement. The decrease was partially offset by an increase in employee related expenses of \$1.6 million and \$3.8 million in the three and six month comparison.

### Sales and Marketing

Sales and marketing expenses increased \$7.0 million to \$21.8 million for the three months ended June 30, 2015, compared to \$14.9 million for the same period in 2014. The increase was mainly the result of a \$4.3 million increase in employee related expenses due to the addition of employees as we continue to expand our sales force. Additionally, we incurred a \$2.0 million increase in costs associated with marketing campaigns, new market opportunities and other strategic initiatives as we continue to expand awareness of the OmniPod System and our on-body injection devices for drug delivery and an additional \$0.7 million increase in travel and entertainment costs.

Sales and marketing expenses increased \$10.7 million to \$39.2 million for the six months ended June 30, 2015, compared to \$28.5 million for the same period in 2014. The increase was mainly the result of a \$7.1 million increase in employee related expenses due to the addition of employees as we continue to expand our sales force. Additionally, we incurred a \$2.7 million increase in costs associated with marketing campaigns as we continue to expand awareness of the OmniPod System and our on-body injection devices for drug delivery and an additional \$0.8 million increase in travel and entertainment costs.

### Interest and Other Expense, Net

Interest and other expense, net was \$3.0 million and \$6.2 million for the three and six months ended June 30, 2015, compared to \$23.8 million and \$28.0 million for three and six months ended June 30, 2014. Decreases in interest and other expense, net in the second quarter and first six months of 2015 compared to the second quarter and first six months of 2014 was primarily related to the loss from extinguishment of long-term debt of \$18.9 million incurred in June 2014. The decrease also reflected the 2% interest rate on our long-term debt in 2015 compared to the 3.75% interest rate in the prior year period.

### Income Tax Expense

Income tax expense was de minimis and \$0.1 million in the three months ended June 30, 2015 and 2014, and \$0.1 million for both the six months ended June 30, 2015 and 2014. Income tax expense is comprised of a current and deferred portion. The current portion primarily related to state and foreign taxes and the deferred portion primarily related to federal and state tax amounts. Additional information regarding income tax expenses is provided in note 13 to the consolidated financial statements included in this Form 10-Q.

### Liquidity and Capital Resources

We commenced operations in 2000 and to date we have financed our operations primarily through private placements of common and preferred stock, secured indebtedness, public offerings of our common stock and issuances of convertible debt.

As of June 30, 2015, we had \$145.1 million in cash and cash equivalents. We believe that our current cash and cash equivalents, together with the cash expected to be generated from sales, will be sufficient to meet our projected operating and debt service requirements for at least the next twelve months.

### Equity

In July 2014, in connection with the extinguishment of \$28.5 million in principal amount of 3.75% Notes (as defined below), we issued 348,535 shares of common stock to the holders representing the conversion value in excess of the principal amount.

Additional information about our common stock issuances is provided in note 12 to the consolidated financial statements included in this Form 10-Q.



Table of Contents

## Debt

We had outstanding convertible debt and related deferred financing costs on our consolidated balance sheet as follows (in thousands):

	As of	
	June 30, 2015	December 31, 2014
Principal amount of the 2% Convertible Senior Notes	\$201,250	\$201,250
Unamortized debt discount	(29,030	) (32,256
Long-term debt, net of discount	\$172,220	\$168,994
Deferred financing costs	\$4,411	\$4,974

Interest expense related to the 3.75% Notes and the 2% Notes was included in interest and other expense on the consolidated statements of operations as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2015	2014	2015	2014
Contractual coupon interest	\$1,006	\$1,273	\$2,012	\$2,621
Accretion of debt discount	1,625	2,258	3,226	4,883
Amortization of debt issuance costs	281	192	563	338
Loss on extinguishment of long-term debt	—	18,943	—	18,943
Total interest and other expense	\$2,912	\$22,666	\$5,801	\$26,785

## 3.75% Convertible Senior Notes

In June 2011, we sold \$143.8 million in principal amount of 3.75% Convertible Senior Notes due June 15, 2016 (the "3.75% Notes"). The interest rate on the notes was 3.75% per annum, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 3.75% Notes were convertible into our common stock at an initial conversion rate of 38.1749 shares of common stock per \$1,000 principal amount of the 3.75% Notes, which was equivalent to a conversion price of approximately \$26.20 per share.

In connection with the issuance of the 3.75% Notes, we repurchased \$70 million in principal amount of the 5.375% Convertible Senior Notes due June 15, 2013 (the "5.375% Notes") for \$85.1 million. The investors that held the \$70 million in principal amount of repurchased 5.375% Notes purchased \$59.5 million in principal amount of the 3.75% Notes and retained approximately \$13.5 million in principal amount of the remaining 5.375% Notes. These investors' combined \$73.0 million in principal amount of convertible debt (\$13.5 million of 5.375% Notes and \$59.5 million of 3.75% Notes) was considered to be a modification of a portion of the 5.375% Notes.

We recorded a total debt discount of \$25.8 million related to the modified debt. This discount consisted of \$10.5 million related to the remaining debt discount on the \$70 million in principal amount of 5.375% Notes repurchased, \$15.1 million related to the premium payment in connection with the repurchase and \$0.2 million related to the increase in the value of the conversion feature. The total debt discount was being amortized as non-cash interest expense at the effective rate of 16.5% over the five year term of the modified debt. Additionally, we paid transaction fees of approximately \$2.0 million related to the modification, which were recorded as interest expense and other expense at the time of the modification.

As of December 31, 2013, the 5.375% Notes were repaid in full and no amounts remained on our balance sheet related to these notes.

In June 2014, in connection with the issuance of \$201.3 million in principal amount of 2% Convertible Senior Notes due June 15, 2019 (the "2% Notes"), we repurchased approximately \$114.9 million in principal amount of the 3.75% Notes for \$160.7 million. Investors that held approximately \$80.0 million of 3.75% Notes purchased approximately \$98.2 million in principal amount of the 2% Notes. The repurchase of the 3.75% Notes was treated as an extinguishment of debt accounted for separately from the issuance of the 2% Notes and allocated to debt and equity based on their respective fair values immediately prior to the transaction.

In June 2014, we met the redemption requirements of the 3.75% Notes and notified holders of our intent to redeem the outstanding \$28.8 million principal amount in July 2014. Prior to the redemption date, holders of \$28.5 million in principal amount of 3.75% Notes notified us that they exercised their right to convert their outstanding 3.75% Notes.

We settled this conversion of the 3.75% Notes in July 2014 by providing cash of \$28.5 million for the principal amount of the outstanding 3.75% Notes converted and issuing 348,535 shares of common stock for the

Table of Contents

conversion premium totaling \$12.6 million, for a total consideration paid of \$41.1 million. We settled the redemption of the remaining \$0.3 million in principal amount in exchange for a cash payment of \$0.3 million representing principal and accrued and unpaid interest. We allocated \$27.9 million of the total consideration paid to the debt and \$13.5 million to equity, and recorded a loss on extinguishment of debt of \$23.2 million in connection with the repurchase and redemption of the 3.75% Notes during the year ended December 31, 2014.

No cash interest expense was recorded related to the 3.75% Notes in the three and six months ended June 30, 2015. Cash interest expense related to the outstanding 3.75% Notes was \$1.1 million and \$2.4 million in the three and six months ended June 30, 2014, respectively.

As of December 31, 2014, no amounts remained outstanding related to the 3.75% Notes.

**2% Convertible Senior Notes**

In June 2014 we sold \$201.3 million in principal amount of the 2% Notes due June 15, 2019. The interest rate on the notes is 2% per annum, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 2% Notes are convertible into our common stock at an initial conversion rate of 21.5019 shares of common stock per \$1,000 principal amount of the 2% Notes, which is equivalent to a conversion price of approximately \$46.51 per share, subject to adjustment under certain circumstances.

We recorded a debt discount of \$35.6 million related to the 2% Notes. The debt discount was recorded as additional paid-in capital to reflect the value of our nonconvertible debt borrowing rate of 6.2% per annum. This debt discount is being amortized as non-cash interest expense over the five year term of the 2% Notes. We incurred deferred financing costs related to this offering of approximately \$6.7 million, of which \$1.2 million has been reclassified as an offset to the value of the amount allocated to equity. The remainder is recorded as other assets in the consolidated balance sheet and is being amortized as non-cash interest expense over the five year term of the 2% Notes.

We determined that the higher interest and tax payments required in certain circumstances are considered embedded derivatives and should be bifurcated and accounted for at fair value. We assess the value of the embedded derivatives at each balance sheet date. The derivatives had de minimis value at the balance sheet date.

Cash interest expense related to the 2% Notes was \$1.0 million and \$0.2 million in the three months ended June 30, 2015 and 2014, respectively, and \$2.0 million and \$0.2 million in the six months ended June 30, 2015 and 2014, respectively. Non-cash interest expense related to the 2% Notes was \$1.9 million and \$0.3 million in the three months ended June 30, 2015 and 2014, respectively, and \$3.8 million and \$0.3 million in the six months ended June 30, 2015 and 2014, respectively.

As of June 30, 2015, we included \$172.2 million on the balance sheet in long-term debt related to the 2% Notes. Additional information regarding our debt issuances is provided in note 4 to the consolidated financial statements included in this Form 10-Q.

**Capital Leases**

As of June 30, 2015 and December 31, 2014, we have approximately \$13.7 million and \$8.0 million of manufacturing equipment acquired under capital leases, respectively. The obligations under the capital leases are being repaid in equal monthly installments over 24 to 36 month terms and include principal and interest payments with an effective interest rate of 13% to 17%. The assets have been recorded at \$13.7 million and are included in property and equipment on our balance sheet as of June 30, 2015.

At June 30, 2015, \$6.2 million was included in current liabilities and \$2.3 million was included in long-term liabilities on our balance sheet related to these capital leases. The aggregate future minimum lease payments related to these capital leases as of June 30, 2015, are as follows (in thousands):

Years Ending December 31,	Minimum Lease Payments
2015 (remaining)	\$3,524
2016	5,639
2017	269
Total future minimum lease payments	\$9,432
Interest expense	(882 )
Total capital lease obligations	\$8,550



Table of Contents

We recorded \$0.4 million and \$0.3 million of interest expense on the capital leases in both the three months ended June 30, 2015 and 2014, respectively. We recorded \$0.7 million and \$0.6 million in the six months ended June 30, 2015 and 2014, respectively.

**Operating Activities**

The following table sets forth the amounts of cash used in operating activities and net loss for each of the periods indicated (in thousands):

	Six Months Ended June 30,	
	2015	2014
Cash used in operating activities	\$(2,703	) \$(509
Net loss	\$(27,266	) \$(35,255

In the six months ended June 30, 2015, net cash used in operating activities was primarily attributable to operations after adjustments for non-cash and other expenses of approximately \$21.7 million. Non-cash and other items included depreciation and amortization of \$7.1 million, stock-based compensation of \$9.6 million, non-cash interest and other expense of \$3.8 million and provision for bad debts of \$1.2 million.

Non-cash and other items used in operating activities was \$41.3 million in the six months ended June 30, 2014, and included a loss from the extinguishment of debt of \$18.9 million, depreciation and amortization of \$6.1 million, stock-based compensation of \$8.6 million, non-cash interest and other expense of \$5.9 million and provision for bad debts of \$1.8 million.

Uses of cash from operations in the six months ended June 30, 2015 was primarily a result of our net loss, an increase of \$5.0 million accounts payable, accrued expenses, and other current liabilities and a decrease in accounts receivable of \$6.9 million offset by an increase of \$10.3 million in inventories.

**Investing and Financing Activities**

The following table sets forth the amounts of cash used in investing activities and cash provided by (used in) financing activities for each of the periods indicated (in thousands):

	Six Months Ended June 30,	
	2015	2014
Cash used in investing activities	\$(4,601	) \$(5,745
Cash provided by financing activities	\$1,248	\$32,072

Cash used in investing activities in the six months ended June 30, 2015 and 2014 was primarily related to purchases of property and equipment, of which the majority related to the purchase of manufacturing equipment for use in the production of the OmniPod System.

Cash provided by financing activities in the six months ended June 30, 2015 was mainly related to the net proceeds from the issuance of common stock related to exercises of employee stock options offset by our payment of taxes in connection with the vesting of the restricted stock units in the period and payment of certain capital lease obligations. Cash provided by financing activities in the six months ended June 30, 2014 mainly related to the net proceeds from the issuance of long-term debt and common stock related to exercises of employee stock options offset by our repayment of debt and payment of taxes in connection with the vesting of the restricted stock units in the period.

**Commitments and Contingencies**

We lease our facilities in Massachusetts, New York, Florida, Canada and Singapore. Our leases are accounted for as operating leases. The leases generally provide for a base rent plus real estate taxes and certain operating expenses related to the leases. In 2013, we entered into a new lease agreement for approximately 90,000 square feet of laboratory and office space for our corporate headquarters in Billerica, Massachusetts. The lease term began in August 2014 and expires in October 2022 and contains escalating payments over the life of the lease. In 2015, we extended our Singapore lease which now expires in July 2016. In 2014, we amended our existing lease for warehouse space in Billerica, Massachusetts which extended the term and increased the approximate square footage under the lease. The lease now expires in September 2019. Additionally, in 2014, we amended our existing lease for office space in New York which now expires in January 2019. Our Florida lease expires in December 2015. In the second quarter of 2015, we entered into a new lease agreement of office space in Ontario, Canada. The lease term began in June 2015 and expires in May 2018.



Table of Contents

Certain of our operating lease agreements contain scheduled rent increases. Rent expense is recorded using the straight-line method and deferred rent is included in other liabilities in the accompanying balance sheets.

The following table summarizes our principal obligations as of June 30, 2015 (in thousands):

Contractual Obligations	Total	Payments Due in					
		2015 (remaining)	2016	2017	2018	2019	Later
Operating lease obligations	\$16,340	\$1,154	\$2,290	\$2,327	\$2,308	\$2,181	\$6,080
Debt obligations <sup>(1)</sup>	217,183	2,013	4,025	4,025	4,025	203,095	—
Capital lease obligations <sup>(2)</sup>	9,432	3,524	5,639	269	—	—	—
Total contractual obligations	\$242,955	\$6,691	\$11,954	\$6,621	\$6,333	\$205,276	\$6,080

(1) The interest rate on the convertible debt is 2% per annum. We have included future payments of interest on the long-term debt in our obligations.

(2) The effective interest rate on the capital lease obligations is 13-17%. We have included future payments of interest on the capital leases in our obligations.

We have replied and are currently awaiting a response in relation to the letter of preliminary audit results received in April 2015 on behalf of the Centers for Medicare and Medicaid Services and the State of New York alleging overpayment of certain Medicaid claims to Neighborhood Diabetes. We believe the likelihood of a loss is reasonably possible. However, due to the preliminary nature of this matter, we are not able to assess its ultimate outcome, or reasonably estimate a range of possible loss.

We are in the process of responding to a letter of preliminary audit results received in June 2015 from the Connecticut Department of Social Services Office of Quality Assurance alleging overpayment of certain Medicaid claims to Neighborhood Diabetes. Due to the preliminary nature of this matter, we are not able to assess its ultimate outcome, or reasonably estimate a range of possible loss.

We received a warning letter from the FDA in June 2015 that related to the release of certain lots of OmniPods that did not conform to final acceptance criteria. A voluntary recall of the identified lots was issued and a range of potential product replacement costs associated with the recall was estimated between \$0.2 million and \$0.4 million. As we are not able to assess the exact liability, \$0.2 million was recorded to warranty expense in the second quarter of 2015. We have replied to the FDA's letter, and received a response indicating that our corrective actions appear to have adequately addressed the issue outlined in the letter.

We have reached a settlement agreement with the Massachusetts Department of Revenue for sales and use tax audits related to Neighborhood Diabetes. Based on the settlement agreement, we recorded a liability of \$0.8 million, which was a reduction of our previously recorded liability of \$3.7 million in connection with the settlement of this matter at June 30, 2015.

On May 5, 2015-June 16, 2015, three class action lawsuits were filed by shareholders in the U.S. District Court, Massachusetts, against us and certain individual current and former executives of the Company. Two suits were voluntarily dismissed. *Arkansas Teacher Retirement System v. Insulet, et al.*, 1:15-cv-12345, alleges violations of Sections 10(b) and 20(a) and Rule 10b-5 of the Securities Exchange Act of 1934 by making allegedly false and misleading statements about our business, operations, and prospects. The lawsuit seeks, among other things, compensatory damages in connection with our allegedly inflated stock price between May 7, 2013 and April 30, 2015, as well as attorneys' fees and costs. In light of the preliminary nature of this matter, we are unable to reasonably assess its ultimate outcome. However, we believe that the resolution of this matter will not have a material adverse effect on its financial condition.

#### Off-Balance Sheet Arrangements

As of June 30, 2015, we did not have any off-balance sheet financing arrangements.

#### Critical Accounting Policies and Estimates

Our financial statements are based on the selection and application of generally accepted accounting principles, which require us to make estimates and assumptions about future events that affect the amounts reported in our financial statements and the accompanying condensed notes. Future events and their effects cannot be determined with

certainty. Therefore, the determination of estimates requires the exercise of judgment. Actual results could differ from those estimates, and any such differences may be material to our financial statements. We have reviewed our policies and estimates to determine our critical accounting policies for the six



Table of Contents

months ended June 30, 2015. We have made no material changes to the critical accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2014.

Recent Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 requires that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Under this guidance, a company may make additional estimates regarding performance conditions and the allocation of variable consideration. The guidance is effective in fiscal years beginning after January 1, 2017, with early adoption permitted. We are currently evaluating the impact of ASU 2014-09. We have not yet selected a transition method nor have we determined the effect of the standard on our consolidated financial position and results of operations.

In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718), Accounting for Share-Based Payments when the terms of an award provide that a performance target could be achieved after the requisite service period ("ASU 2014-12"). ASU 2014-12 clarifies the period over which compensation cost would be recognized in awards with a performance target that affects vesting and that could be achieved after the requisite service period. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective in fiscal years beginning after January 1, 2016, with early adoption permitted. We are currently evaluating the impact of ASU 2014-12.

In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"). ASU 2015-03 amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. The guidance is effective for annual reporting periods beginning after December 15, 2015, and must be applied retrospectively. Early adoption is permitted. Had we adopted ASU 2015-03, other noncurrent assets and long-term debt would both have been \$4.4 million and \$5.0 million lower as of June 30, 2015 and December 31, 2014, respectively.

In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory ("ASU 2015-11"). ASU 2015-11 amends existing guidance and requires entities to measure most inventory at the lower of cost and net realizable value. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. Upon adoption, entities must disclose the nature of and reason for the accounting change. We are currently evaluating the impact of ASU 2015-11.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We do not use derivative financial instruments in our investment portfolio and have no foreign exchange contracts. Our financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, accrued expenses and long-term obligations. We consider investments that, when purchased, have a remaining maturity of 90 days or less to be cash equivalents. The primary objectives of our investment strategy are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. To minimize our exposure to an adverse shift in interest rates, we invest mainly in cash equivalents. We do not believe that a 10% change in interest rates would have a material impact on the fair value of our investment portfolio or our interest income.

As of June 30, 2015, we had outstanding debt recorded on our consolidated balance sheet of \$201.3 million related to our 2% Notes and \$8.6 million related to capital lease obligations. As the interest rates are fixed, changes in interest rates do not affect the value of our debt or capital lease obligations.

**Foreign Currency Exchange Risk.** Our business is subject to risks, including, but not limited to: unique economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. Fluctuations in foreign currency rates could affect our sales, cost of goods and operating margins and could result in exchange losses. In addition, currency devaluations can result in a loss if we hold deposits of that currency. A hypothetical 10% increase or decrease in foreign currencies that we transact in would not have a material adverse impact on our business, financial condition or results of operations.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

As of June 30, 2015, our management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) under the supervision and with the participation of our chief executive officer and chief financial officer. In designing and evaluating our disclosure controls and procedures, we and our management recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating and implementing possible controls and procedures. Based upon that evaluation of our disclosure controls and procedures as of June 30, 2015, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, including ensuring that such material information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Information regarding our legal proceedings is provided in note 11 to the consolidated financial statements in this Form 10-Q.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect our business, financial condition or future results. These risks are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

Exhibit Number	Description of Document
10.1	Form of Canada Non-Qualified Stock Option Agreement for Company Employees under the Insulet Corporation Second Amended and Restated 2007 Stock Option and Incentive Plan
10.2	Form of Canada Time Vesting Restricted Stock Unit Agreement under the Insulet Corporation Second Amended and Restated 2007 Stock Option and Incentive Plan
10.3	Form of Performance Vesting Restricted Stock Unit Agreement under the Insulet Corporation Second Amended and Restated 2007 Stock Option and Incentive Plan
10.4	Form of Incentive Stock Option Agreement under the Insulet Corporation Third Amended and Restated 2007 Stock Option and Incentive Plan
10.5	Insulet Corporation Third Amended and Restated 2007 Stock Option and Incentive Plan (previously filed as Appendix A to the Company's Definitive Proxy Statement on April 2, 2015 and incorporated by reference herein)
10.6	Agreement by and between Insulet Corporation and Allison Dorval dated April 1, 2015 (previously filed as Exhibit 10.1 to the Company's Current Report on Form 8-K on April 1, 2015 and incorporated by reference herein)
10.7	Agreement by and between Insulet Corporation and Patrick Ryan dated June 25, 2015 (previously filed as Exhibit 10.1 to the Company's Current Report on Form 8-K on June 30, 2015 and incorporated by reference herein)
31.1	Certification of Patrick J. Sullivan, President and Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Michael Levitz, Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Patrick J. Sullivan, President and Chief Executive Officer, and Michael Levitz, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following materials from Insulet Corporation's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, formatted in XBRL (eXtensible Business Reporting Language), as follows: <ul style="list-style-type: none"> <li>(i) Consolidated Balance Sheets as of June 30, 2015 (Unaudited) and December 31, 2014</li> <li>(ii) Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2015 and June 30, 2014 (Unaudited)</li> <li>(iii) Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2015 and June 30, 2014 (Unaudited)</li> </ul>

(iv) Condensed Notes to Consolidated Financial Statements (Unaudited)

\* Furnished herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INSULET CORPORATION

(Registrant)

Date: August 12, 2015

/s/ Patrick J. Sullivan  
Patrick J. Sullivan  
President and Chief Executive Officer  
(Principal Executive Officer)

Date: August 12, 2015

/s/ Michael L. Levitz  
Michael L. Levitz  
Chief Financial Officer  
(Principal Financial and Accounting Officer)